semaglutide gastrointestinal obstruction class action in dallas Once-weekly semaglutide 7·2 mg adults with obesity (STEP UP): a randomised, controlled, phase 3b trial SURGE IN GLP-1 DRUGS LIKE

Characterizing decision-making and reward processing in bipolar disorder: a cluster analysis

Her work focuses on helping people improve their health using science-based strategies

The Ozempic litigation is a coordinated mass tort involving claims that Novo Nordisk failed to warn consumers and healthcare providers about the risk of serious gastrointestinal side effects linked to semaglutide, including complications that can require emergency care or hospitalization

Other factors, like side effects and costs, should also be considered

We can prescribe the new Wegovy pill or the Wegovy pen, if eligible

Personalized Dosing GLP-1 therapy is not one-size-fits-all